University of Basel

Department of
Clinical Research

/ The Lancet Oncology

Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer.

Rentsch CA, Hayoz S, Cathomas R.

Lancet Oncol. 2021 Sep;22(9):e379.

Back

To top

Quick Links